467 related articles for article (PubMed ID: 33430494)
1. Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update.
Hsu JF; Chu SM; Liao CC; Wang CJ; Wang YS; Lai MY; Wang HC; Huang HR; Tsai MH
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430494
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
[TBL] [Abstract][Full Text] [Related]
3. Nanotechnology for Treatment of Glioblastoma Multiforme.
Michael JS; Lee BS; Zhang M; Yu JS
J Transl Int Med; 2018 Sep; 6(3):128-133. PubMed ID: 30425948
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
[TBL] [Abstract][Full Text] [Related]
5. Nose-to-brain drug delivery for the treatment of glioblastoma multiforme: nanotechnological interventions.
Kumar N; Khurana B; Arora D
Pharm Dev Technol; 2023 Dec; 28(10):1032-1047. PubMed ID: 37975846
[TBL] [Abstract][Full Text] [Related]
6. Drug delivery approaches for the treatment of glioblastoma multiforme.
Fakhoury M
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
[TBL] [Abstract][Full Text] [Related]
7.
Gallego L; Ceña V
Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861
[TBL] [Abstract][Full Text] [Related]
8. Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment.
Zhao C; Zhu X; Tan J; Mei C; Cai X; Kong F
Biomed Pharmacother; 2024 Feb; 171():116113. PubMed ID: 38181717
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery.
Brar HK; Jose J; Wu Z; Sharma M
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678688
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Monoclonal Antibodies Delivery for the Glioblastoma Treatment.
Sousa F; Moura RP; Moreira E; Martins C; Sarmento B
Adv Protein Chem Struct Biol; 2018; 112():61-80. PubMed ID: 29680243
[TBL] [Abstract][Full Text] [Related]
11. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.
Choudhury H; Pandey M; Chin PX; Phang YL; Cheah JY; Ooi SC; Mak KK; Pichika MR; Kesharwani P; Hussain Z; Gorain B
Drug Deliv Transl Res; 2018 Oct; 8(5):1545-1563. PubMed ID: 29916012
[TBL] [Abstract][Full Text] [Related]
12. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment
Yang J; Shi Z; Liu R; Wu Y; Zhang X
Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Bikhezar F; de Kruijff RM; van der Meer AJGM; Torrelo Villa G; van der Pol SMA; Becerril Aragon G; Gasol Garcia A; Narayan RS; de Vries HE; Slotman BJ; Denkova AG; Sminia P
J Neurooncol; 2020 Jan; 146(2):239-246. PubMed ID: 31875307
[TBL] [Abstract][Full Text] [Related]
14. Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles.
Miranda A; Blanco-Prieto MJ; Sousa J; Pais A; Vitorino C
Int J Pharm; 2017 Oct; 531(1):389-410. PubMed ID: 28801108
[TBL] [Abstract][Full Text] [Related]
15. Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models.
Kovacs Z; Werner B; Rassi A; Sass JO; Martin-Fiori E; Bernasconi M
J Control Release; 2014 Aug; 187():74-82. PubMed ID: 24878186
[TBL] [Abstract][Full Text] [Related]
16. Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies.
Liu D; Dai X; Ye L; Wang H; Qian H; Cheng H; Wang X
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Jan; 15(1):e1838. PubMed ID: 35959642
[TBL] [Abstract][Full Text] [Related]
17. Potential of Nanocarrier-Associated Approaches for Better Therapeutic Intervention in the Management of Glioblastoma.
Vikram ; Kumar S; Ali J; Baboota S
Assay Drug Dev Technol; 2024; 22(2):73-85. PubMed ID: 38193798
[No Abstract] [Full Text] [Related]
18. Targeted Vascular Drug Delivery in Cerebral Cancer.
Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma Multiforme-A Look at the Past and a Glance at the Future.
King JL; Benhabbour SR
Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371744
[TBL] [Abstract][Full Text] [Related]
20. Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable.
Barzegar Behrooz A; Talaie Z; Syahir A
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
